Drug repurposing as a potential source of innovative therapies in cervical cancer

Rica Capistrano I. 1, Sonz Paul, 2 Ingrid Boere, 3 Pan Pantziarka, 1, 4 Supriya Chopra, 5 Remi A Nout, 3 Gauthier Bouche 1

ABSTRACT

Objective Drug repurposing is an alternative development pathway that utilizes the properties of drugs approved for other diseases and builds on available safety and pharmacological data to develop the drug as a potential treatment for other diseases. A literature-based approach was performed to identify drug repurposing opportunities in cervical cancer to inform future research and trials.

Methods We queried PubMed for each drug included in two databases (ReDO_DB and CDcervix_DB), which include 300+ non-cancer drugs and 200+ cancer drugs not used in cervical cancer, respectively) and manually assessed all abstracts for relevance and activity in cervix cancer, and type of evidence. Subsequently, we also performed a search of clinical trial databases where we generated a list of registered trials in cervical cancer with all drugs from our databases.

Results Of the 534 drugs from both databases, 174 (33%) had at least one relevant abstract or registered trial in cervical cancer. 94 (18%) drugs had at least human data available, and 52 (10%) drugs were evaluated in registered trials. To prioritize drugs to consider for future trials, all 174 drugs were further assessed for strength of scientific rationale, feasibility for integration in cervical cancer standard of care, evidence of radiosensitization, and potential mechanism of action. Out of the 174 drugs, 38 (22%) potential drug candidates were selected.

Conclusion This study resulted in a list of candidate drugs for potential evaluation in cervical cancer. Many drugs might warrant additional (pre)clinical investigation, which could be done in a coordinated manner using platform trials.

INTRODUCTION

Cervical cancer is the fourth most common cancer in terms of incidence and mortality in women worldwide.1 In countries with inadequate screening programs, it remains a significant cause of morbidity and mortality. In the treatment of patients with locally advanced cervical cancer, there has been little improvement in systemic therapy since the implementation of cisplatin as a radiosensitizer.2 Neoadjuvant chemotherapy followed by radical surgery does not improve disease-free survival or overall survival compared with platinum-based chemoradiation.3 4 Adjuvant chemotherapy combinations have not yielded any survival benefit either and have led to more severe side-effects than chemoradiation alone.5

This lack of benefit of adjuvant chemotherapy was recently confirmed by the results of the international OUTBACK trial.6

For patients with metastatic cervical cancer, the addition of pembrolizumab to standard palliative chemotherapy resulted in a modest overall survival benefit in selected patients.7 More recently, adding pemlobizumab to chemotherapy and bevacizumab led to improvements in progression-free survival and overall survival in patients with recurrent, persistent, or metastatic cervical cancer.8 In second-line treatment of metastatic cervical cancer, cemiplimab improved overall survival by a median of 3.5 months.9 Earlier phase studies have shown promising clinical activity with anti-PD-1 combined with anti-CTLA4 antibody or with the antibody-drug conjugate tisotubumab vedotin.10 11 However, expensive targeted agents remain inaccessible to a vast majority of patients worldwide.12 Therefore broadening research in cervical cancer and exploring new and other opportunities is essential.

Drug repurposing is an alternative development pathway that utilizes the properties of drugs approved for other diseases and builds on available safety and pharmacological data to develop new potential treatment options for a specific indication.12 Classical

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ There has been previous publication regarding repurposing drugs in cervical cancer but focusing on only radiosensitizing agents.

WHAT THIS STUDY ADDS

⇒ This comprehensive literature search resulted in a list of 38 potential drug candidates that warrant further investigation. This study highlights the basic characteristics of these drug candidates, summarizes relevant data on cervical cancer, and lists the registered cervical cancer trials and main results of human data.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This study provides a list of potential drug candidates that may be consulted to assist drug development, and potentially expand treatment options for cervical cancer patients.
Original research

examples in oncology are thalidomide for multiple myeloma, imatinib for gastrointestinal stromal tumors, and zoledronic acid for bone metastases. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. In this project a database of candidate drugs with at least one peer-reviewed publication showing relevant anticancer activity has been curated. This database, termed ReDO_DB, has been made available online.

Another comprehensive list of approved anticancer drugs, termed CancerDrugs_DB, has been generated as well. Here, we sought to identify drug repurposing opportunities in cervical cancer by screening the literature and clinical trial databases in a systematic manner using the two aforementioned databases and used this to inform future research and trials.

METHODS

A literature-based approach was undertaken to identify which drugs from ReDO_DB or CancerDrugs_DB have been reported to be active in cervical cancer. ReDO_DB is a database of non-cancer drugs available for commercial purposes for which at least one article reported a possible effect on cancer, irrespective of the cancer type. ReDO_DB included 317 drugs at the time this work was performed. CancerDrugs_DB is a list of drugs approved in the treatment of one or more malignancies by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or national regulatory agencies. Since CancerDrugs_DB already contained drugs used and approved in cervical cancer, CDcervix_DB was created, which is a subset of the CancerDrugs_DB of 217 drugs after all drugs mentioned in the cervix cancer National Comprehensive Cancer Network guidelines and assimilated drugs were subtracted from CancerDrugs_DB. A list of all queried drugs included in both databases are available in the Online supplemental table S1.

The specific methodology to interrogate PubMed and the clinical trials databases (clinicaltrials.gov and World Health Organization-International Clinical Trials Registry Platform (WHO-ICTRP)) has been published. In brief, a dataset of abstracts and other publications for abstract assessment. In case the abstracts were deemed relevant, the type of evidence (in vitro, in vivo, case reports, observational studies, clinical trials, or review) was indicated.

Subsequently, a search of clinical trials databases (clinicaltrials.gov and WHO-ICTRP) was performed and a list of registered cervical cancer trials was generated by combining the search term ‘cervical cancer’ and any drugs from the ReDO_DB and CDcervix_DB. This search was completed on January 5, 2022. All trials were also assessed for their relevance, and any publications linked to relevant trials were searched and assessed using the same method as for abstract assessment.

To prioritize drugs to consider for future trials, relevant trials and abstracts and the corresponding published research were further assessed for each drug, independently by at least two of the authors (RC, SP, IB, PP and GB), with the instruction to tag drugs that should be excluded because of weak or limited evidence of efficacy (drugs with only in vitro results on a single cell line, drugs with negative or contradictory results), or non-supportive results in reported trials (results not justifying further investigation according to the assessors). Discrepant results were discussed until a consensus was reached. For each drug from the final selection, the type of evidence (in vitro results and/or in vivo results and/or human publications and/or registered trials) and the amount of data per relevant drug were summarized.

In accordance with the journal’s guidelines, the authors will provide our data for independent analysis by a selected team by the editorial team for the purposes of additional data analysis or for the reproducibility of this study in other centers if such is requested.

RESULTS

Of the 534 drugs queried, 174 had at least one relevant abstract or registered trial in cervical cancer, 90 and 84 drugs from ReDO_DB and CDcervix_DB, respectively. Ninety-four drugs had at least human data available, with 52 drugs being or have been evaluated in registered trials. Only 41 drugs from the queried list had at most in vitro data. The results are summarized in Table 1. Of the 174 drugs with at least one relevant abstract or trial, 136 drugs were excluded during the prioritization step because of weak or limited evidence of efficacy or non-supportive results in prior trials.

| Table 1 | Summary results of queries |
|-----------------|-----------------|-----------------|-----------------|
| **Number of drugs** | **REDO** | **CDcervix** | **Total** |
| Queried | 317 | 217 | 534 |
| With at least one relevant abstract or trial in cervical cancer | 90 (28%) | 84 (39%) | 174 (33%) |
| With human data | 36 (11%) | 58 (27%) | 94 (18%) |
| With registered trials | 14 (4%) | 38 (18%) | 52 (10%) |
| With no human data | 54 (17%) | 26 (12%) | 80 (15%) |
| **In vitro only** | 32 (10%) | 9 (4%) | 41 (8%) |
The type and amount of data are summarized in Table 2 for the 38 drugs (22%) deemed to be potential repurposing candidates. For the drugs not selected, the data are available as Online supplemental table S2.

For the 38 potential repurposing candidates, the scientific rationale and feasibility for integration in cervical cancer standard of care were reviewed. Table 3 presents basic characteristics of each drug (patent status and main approved indications) and summarizes relevant data on cervical cancer (the potential mechanism of action, available biomarker, possible role (radiosensitizer and/or immunomodulator)) based on the data found in the relevant publications for each drug. It also lists the registered cervical cancer trials and main results of human data currently available. In addition, it outlines the potential setting in which these drug candidates can be repurposed based on the data found in the publications and the combined general knowledge of the authors.
| Drug | Main approved indications | Off-patent Mechanism of action(s) in cervical cancer | Candidate biomarker(s) | Registered cervical cancer trials and main results of human data | Role(s)* | Potential setting in cervical cancer |
|------|---------------------------|-----------------------------------------------------|------------------------|---------------------------------------------------------------|---------|-----------------------------------|
| Arsenic trioxide | Acute promyelocytic leukemia | Yes Prevention of migration through CXCR4 inhibition, direct cytotoxicity, radiosensitization | No prominent biomarker identified | NCT00005999: completed trial with single agent in recurrent setting; No results available. ChiCTR190023822: ongoing trial as neoadjuvant treatment with carboplatin. No results available | Yes No | First line, with chemoradiotherapy |
| Artesunate | Malaria | Yes Direct cytotoxicity, radiosensitization, enhancement of TRAIL-induced cell death, inhibition of HOTAIR expression | No prominent biomarker identified | None | Yes No | Recurrent/metastatic |
| Atovaquone | Toxoplasmosis, Pneumocystis carinii pneumonia | Yes Inhibition of mitochondrial respiratory chain complex III | Hypoxia biomarker(s) | None | No No | Recurrent/metastatic |
| Bortezomib | Multiple myeloma, mantle cell lymphoma | Yes Inhibition of NF-κB, proteasomal activity and hypoxia-related HIF-1α expression, enhancement of the apoptosis-inducing TRAIL receptor antibody efficacy and induction of apoptosis | No prominent biomarker identified | NCT00106262: terminated trial because of lack of accrual. NCT00329589: completed trial in combination with chemoradiotherapy. No results available | Yes Yes | First line, with chemoradiotherapy |
| Cetuximab | Squamous cell head and neck cancer, colorectal cancer | Yes Inhibition of EGFR, radiosensitization | EGFR protein expression | NCT00957411, NCT0101192, NCT00499031, NCT0104910, NCT0018193, NCT0097009: 6 completed or terminated trials with results available, although always showing limited or no benefit; 2006-003759-19 and NCT00292955: trials with unknown status or prematurely terminated without any results available | Yes No | First line, with chemoradiotherapy |
| Chlorpromazine | Psychotic disorders, nausea and vomiting, anxiety, hiccups | Yes Radiosensitization | No prominent biomarker identified | No registered trial, but publication of human data showing a 53% complete response in combination with radiotherapy compared with 39% complete response with radiotherapy alone | Yes No | First line, with chemoradiotherapy |
| Cidofovir | CMV-retinitis in AIDS | Yes Decrease E6 and E7 expression, DNA damage by incorporation into DNA, radiosensitization | No prominent biomarker identified | NCT02515877 and NCT00811408: Prematurely discontinued trials showing a complete response in 8 out of 9 patients with 2 year and 4 year overall survival rates estimated at 93% and 84%, respectively, and 2 year progression-free survival is 76% | Yes No | First line, with chemoradiotherapy |

Continued
| Drug characteristics       | Relevant data on cervical cancer                                                                 | Potential setting in cervical cancer          |
|----------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------|
| Decitabine                 | Intake of the nucleic acid synthesis No prominent biomarker identified                          | No No Recurrent/metastatic                   |
| Acute myeloid leukemia     |                                               |                                             |
| Deferoxamine               | Increase hCt1 and TIR1 expression through upregulation of Sp1 and induce TIR1 expression through the Sp1-NF-κB p65-dependent pathway, platinum sensitization No prominent biomarker identified None | No No First line, with chemoradiotherapy Recurrent/metastatic |
| Acute iron intoxication, chronic iron overload |                                               |                                             |
| Doxycycline                | Direct cytotoxic, inhibition of MMP2 and MMP9 expression, induction of apoptosis and inhibition of EMT and migration No prominent biomarker identified | NCT02874430: ongoing phase II trial. No results available No No First line, with chemoradiotherapy Recurrent/metastatic |
| Respiratory, urinary tract and ophthalmic infection |                                               |                                             |
| Erlotinib                  | Inhibition of EGFR EGFR protein expression NCT00031993: completed trial showing a 94% complete response in combination with chemoradiotherapy. The 2 year and 3 year cumulative overall- and progression-free survival rates were 92% and 81%, and 80% and 74%, respectively. As single agent erlotinib seems to be inactive. NCT00428194: withdrawn trial because of lack of accrual | No No First line, with chemoradiotherapy Recurrent/metastatic |
| Non-small cell lung cancer, pancreatic cancer |                                               |                                             |
| Everolimus                 | Radiosensitization, induction of apoptosis by targeting PI3K/AKT/mTOR pathways, inhibition of proliferation by inactivation of the HPV E7 oncoprotein Alterations in the PI3k/AKT/mTOR pathway NCT00428194: completed trial determining 5 mg/day as maximum tolerated dose of everolimus in combination with cisplatin and radiotherapy in locally advanced patients. NCT00967928: withdrawn trial because of lack of enrollment | Yes No First line, with chemoradiotherapy |
| Neuroendocrine tumors, renal cell carcinoma, HR+ breast cancer |                                               |                                             |
| Fulvestrant                | Inhibition of aromatase ER-α expression in stromal cells NCT04579380: ongoing phase II trial. No results available | No No First line, with chemoradiotherapy Recurrent/metastatic |
| HR+ breast cancer          |                                               |                                             |
| Gefitinib                  | Inhibition of EGFR EGFR protein expression No results available for the registered trials (CTRI/2017/12/010726 and NCT00049556), but publication of human data resulting in a median disease-free interval of 15 months in advanced or metastatic patients after recurrence. The median progression-free survival and median overall survival were 4 months and 5 months, respectively. Neoadjuvant chemotherapy, chemoradiation, followed by gefitinib maintenance in patients with locally advanced cervical cancer showed a 3 year overall survival of 70%, and 3 year progression-free survival of 51% | No No First line, maintenance Recurrent/metastatic |
| Non-small cell lung cancer |                                               |                                             |

Table 3 Continued
| Drug characteristics | Relevant data on cervical cancer | Potential setting in cervical cancer |
|----------------------|----------------------------------|-------------------------------------|
| **Hydralazine and valproate** | Hypertension (hydralazine), epilepsy and bipolar disorder (valproate) | Inhibition of HDAC and DNA methyltransferase, unmasking of chronic viral infection (valproate) No prominent biomarker identified NCT00532818 and NCT00404326: 2 completed trials on the combination showing improved progression-free survival in combination with topotecan/cisplatin over topotecan/cisplatin alone, also safety data with chemoradiotherapy | Yes Yes First line, with chemoradiotherapy First line, adjuvant Recurrent/metastatic |
| **Interferon α-2b** | Hairy cell leukemia, chronic hepatitis B and C | Immunomodulation No prominent biomarker identified NCT00138151: terminated trial showing that IFN α-2b in combination with paclitaxel and 13-cis retinoic acid is safe. Mixed results in other trials and limited role with radiotherapy, though results of one trial support testing IFN α-2b given before radiotherapy | Yes Yes First line, with chemoradiotherapy |
| **Ipilimumab** | Melanoma, renal cell carcinoma, non-small cell lung cancer | Inhibition of CTLA4 on T-cells No prominent biomarker identified NCT01711515: completed trial showing safety and preliminary efficacy as adjuvant therapy after chemoradiotherapy, NCT01693783 (phase II), NCT04256213, NCT03508570 (phase I), NCT03755739 (phase II-H), NCT03452332 (phase I): 5 trials ongoing. No results available | No Yes First line, adjuvant Recurrent/metastatic |
| **Lovastatin** | Hypercholesterolemia, coronary heart disease | Inhibition of the mevalonate pathway HMG-CoA reductase expression No registered trial, but publication of human data defining recommended phase II dose and showing disease stabilization in 3/12 recurrent or metastatic cervical cancer patients²³ | Yes No First line, with chemoradiotherapy Recurrent/metastatic |
| **Lurbinectedin** | Squamous cell lung cancer | DNA alkylation, elimination of cancer stem cells, inhibition of myeloid-derived suppressor cells No prominent biomarker identified None | Yes Yes First line, adjuvant Recurrent/metastatic |
| **Melatonin** | Primary insomnia | Production of reactive oxygen species in cancer cells (pro-oxidant) No prominent biomarker identified None | Yes No First line, with chemoradiotherapy Recurrent/metastatic |
| **Metformin** | Diabetes type 2 | Inhibition of mitochondrial respiratory complex I leading to decreased tumor hypoxia and to radiosensitization Hypoxia biomarker(s) NCT02874430, NCT04275713 and NCT02384652: 3 phase II trials ongoing. No results available. | Yes No First line, with chemoradiotherapy Recurrent/metastatic |
| **Mifepristone** | Abortion, Cushing syndrome | Enhancement of chemoradiotherapy, prevention of cell migration No prominent biomarker identified None | Yes No First line, with chemoradiotherapy Recurrent/metastatic |
| **Nelfinavir** | HIV | Inhibition of PI3K-Akt and induction of endoplasmic reticulum stress No prominent biomarker identified NCT03258916: ongoing phase III trial. NCT01485731 and NCT02363829: completed trials showing safety and tolerability of 1250 mg twice daily added to cisplatin-based chemoradiotherapy in patients with locally advanced cervical cancer | Yes No First line, with chemoradiotherapy |
| **Niclosamide** | Tapeworm infections | Inhibition of mitochondrial respiratory complex I and mTOR No prominent biomarker identified None | Yes No First line, with chemoradiotherapy Recurrent/metastatic |
| Drug characteristics | Relevant data on cervical cancer | Potential setting in cervical cancer |
|----------------------|---------------------------------|-------------------------------------|
| Nicotinamide         | Pellagra (Yes)                   | First line, with chemoradiotherapy  |
|                     | Multiple, including radiosensitization (with carbogen in particular) through ROS generation and decreased hypoxia | Recurrent/metastatic                |
|                     | Hypoxia biomarker(s)             |                                     |
|                     | No registered trial, but publication of human data showing safety with chemoradiotherapy and carbogen |                                     |
| Niraparib            | Ovarian cancer (No)              | First line, with chemoradiotherapy  |
|                     | Inhibition of PARP, radiosensitization and platinum sensitization | First line, adjuvant                |
|                     | No prominent biomarker identified | First line, maintenance             |
|                     | NCT04395612, NCT0468753, NCT03644342 and EudraCT2019-001226-10: 4 ongoing phase II trials. No results available |                                     |
| Olaparib             | Ovarian cancer (No)              | First line, with chemoradiotherapy  |
|                     | Inhibition of PARP, radiosensitization and platinum sensitization | First line, adjuvant                |
|                     | Poly-ADP-riboseylation level     | First line, maintenance             |
|                     | NCT04641728, NCT0487587, NCT04483544, NCT03162627, jRCT2031210096 and NCT01237067: 4 ongoing phase II, 1 ongoing phase I, and 1 completed trials. No results available |                                     |
| Pazopanib            | Renal cell carcinoma, soft tissue sarcoma (No) | First line, adjuvant                |
|                     | Inhibition of VEGF and PDGF receptors (anti-angiogenesis) | First line, maintenance             |
|                     | No prominent biomarker identified | First line, adjuvant                |
|                     | NCT00430781 and NCT00561795: 2 completed trials showing an overall response rate of 9% as single agent and increased progression-free survival and overall survival compared with lapatinib. NCT02348398: withdrawn trial. No results available | First line, maintenance             |
| Plerixafor           | Mobilization of hematopoietic stem cells (No) | First line, with chemoradiotherapy  |
|                     | Prevention of chemoradiotherapy-induced CXCL12/CXCR4 signaling resulting in intratumoral accumulation of myeloid cells |                                     |
|                     | No prominent biomarker identified |                                     |
|                     | None |                                     |
| Porfimer             | Esophageal cancer (Yes)          | Recurrent/metastatic                |
|                     | Radiosensitization by enhanced production of reactive oxygen species |                                     |
|                     | No prominent biomarker identified |                                     |
|                     | No registered trial, but case report showing a complete response |                                     |
| Ribavirin            | Hepatitis C (Yes)                | First line, with chemoradiotherapy  |
|                     | Inhibition of eIF4E to overcome chemotherapy resistance | First line, metastatic              |
|                     | Eukaryotic translation initiation factor 4E expression | First line, metastatic              |
|                     | None |                                     |
| Ribociclib           | Breast cancer (No)               | Recurrent/metastatic                |
|                     | Inhibition of cyclin-dependent kinase 4 and 6 | First line, metastatic              |
|                     | No prominent biomarker identified | First line, metastatic              |
|                     | None |                                     |
| Rucaparib            | Ovarian cancer (No)              | First line, with chemoradiotherapy  |
|                     | Inhibition of PARP, radiosensitization and platinum sensitization | First line, adjuvant                |
|                     | No prominent biomarker identified | First line, maintenance             |
|                     | NCT03476798, NCT04171700 and NCT03795272: 2 ongoing phase II trials and one withdrawn trial. No results available |                                     |
| Ruxolitinib          | Myeloproliferative neoplasms (No) | First line, with chemoradiotherapy  |
|                     | Restoration of CADM1, radiosensitization | First line, adjuvant                |
|                     | Loss of CADM1 expression         | First line, maintenance             |
|                     | None |                                     |
| Sakituzumab govitcan | Recurrent triple negative breast cancer (No) | Recurrent/metastatic                |
|                     | Inhibition of DNA topoisomerase I following cell internalization after binding to Top-2, antibody-dependent cellular cytotoxicity | First line, metastatic              |
|                     | Trop-2 expression                | First line, metastatic              |
|                     | None |                                     |
**DISCUSSION**

**Summary of Main Results**

Of the more than 500 drugs that have been screened, we found data supporting a possible therapeutic role in cervical cancer for 38 of them. The list contains drugs already approved for other cancer indications as well as for non-cancer indications, for example, the antibiotic doxycycline or antipsychotic chlorpromazine. We have highlighted not only some basic characteristics of the listed drugs but also a summary of relevant data on cervical cancer, an overview of the registered trials in cervical cancer, and any relevant published human results. For all 38 drugs, a potential setting in which these drugs can be used are suggested.

**Results in the Context of Published Literature**

Our study identified drug repurposing opportunities in cervical cancer. Other work has been published in the past but with a focus on only radiosensitizing agents.17 Sonidegib (Odomzo) is a hedgehog pathway inhibitor approved by the EMA and FDA since 2015 to treat adults with locally advanced basal cell carcinoma that is not treatable with surgery or radiotherapy. The hedgehog pathway could represent a valid cervical cancer therapeutic target. Sonidegib enhances the efficacy of cisplatin-based chemoradiotherapy in a cervical cancer xenograft model without increasing gastrointestinal toxicity. We consider that targeting the hedgehog pathway in patients undergoing chemoradiotherapy with sonidegib is therefore a promising hypothesis.18 With no cervical cancer trials using sonidegib, a logical next step would be to further explore its mechanism of action and confirm activity in a preclinical assessment, and then run an early phase clinical trial evaluating its addition to chemoradiation in cervical cancer.

Another example is the drug nelfinavir (Viracept), a protease inhibitor used against HIV. There is a wealth of preclinical data on the potential use of nelfinavir in cervical cancer.17 Several clinical trials are being conducted (or have been completed) to determine whether nelfinavir is effective as a cancer therapeutic agent in humans. Most of those trials are in cancer types where chemoradiotherapy is a major component of the treatment, such as rectal cancer, non-small cell lung cancer, prostate and pancreatic cancers, with the largest benefits seen in platinum-based chemotherapies such as olaparib (Zejula), niraparib (Zejula), olaparib (Lynparza), and rucaparib (Rubraca)—are another example. This class of drugs has shown activity in ovarian, breast, prostate and pancreatic cancers, with the largest benefits seen in BRCA1/2 mutated ovarian cancer. Mainly it is used as a maintenance treatment after response to platinum-based chemotherapy. PARP is an intracellular protein involved in the repair of single stranded DNA breaks and is found at higher levels in cervical
cancer cells compared with normal cells. In vitro and in vivo data suggest that PARP inhibitors are highly active in cervical cancer preclinical models. PARP inhibitors compromise DNA repair and prevent repair of single strand breaks. They also work synergistically with other DNA damaging agents inducing DNA breaks, such as cisplatin and radiotherapy. Rucaparib also exerts antiproliferative effects and showed potential as a radiosensitizer in cervical cancer in vitro. Aside from preclinical studies, there are several ongoing trials investigating PARP inhibitor therapies in cervical cancer patients. Unfortunately, no clinical results are available yet for these three PARP inhibitors. For niraparib, four ongoing trials have been registered (NCT04395612, NCT04068753, NCT03644342, and EudraCT2019-001226-10). Three trials have been registered for rucaparib, with one withdrawn (NCT03795272) and two ongoing (NCT03476798 and NCT04171700). For olaparib, five trials are ongoing (NCT04641728, NCT04487587, NCT04483544, NCT03162627, and jRCT2031210096) and one has been completed (NCT01237067). The data on the efficacy of PARP inhibitors in cervical cancer are still limited and the results of the aforementioned studies will hopefully determine if PARP inhibitors have a role in the treatment of cervical cancer either as a low dose radiosensitizer or as maintenance treatment. These are just examples of potential repurposing candidates. Two are in a more advanced stage of drug development, while one is still in an early phase and warrants further investigations.

Strengths and Weaknesses

With this systematic approach, we have captured potential repurposing candidates in cervical cancer. Although our ReDO_DB and CancerDrugs_DB contain an extensive list of drugs, we might have missed approved drug products with published activity against cervical cancer. For instance, a trial testing the combination of an approved human papillomavirus preventive vaccine with an anti-PD-1 antibody is ongoing in China in cervical cancer patients (NCT04096911). Also, the biology of cervical cancer together with data from other cancer types may form a strong rationale for the repurposing of other drugs in cervical cancer. Maraviroc, a CCR5 inhibitor used in HIV, is such an example with a strong rationale for targeting CCR5 in cervical cancer, and clinical data coming from other cancer types. Recent data also point to the rationale of combining warfarin, acting as a MERTK inhibitor, with radiotherapy. Another limitation is that the assessment of the available data and the selection of the candidates, although performed by our multidisciplinary team, remains subjective. For some drugs, it was clear that the published activity is probably not worthy of further investigation due to negative activity or lack of activity. As an example, sorafenib showed in a phase I clinical trial a potential detrimental effect, or the drug celecoxib, for which it was shown in two trials that the potential toxicity of COX-2 inhibitors probably offsets any small benefit that might exist. But what most drugs have in common is that additional (pre)-clinical studies are still needed. This list therefore identifies drugs that, based on their scientific properties, may enhance chemoradiotherapy or may have a synergistic effect with radiotherapy or immune therapy. But ultimately, in most cases, the existing scientific evidence for their effects on cancer is limited and further scientific and clinical research is warranted.

Implications for Practice and Future Research

Since limited success in the discovery of new cancer therapies that are widely applicable has occurred in cervical cancer, drug repurposing represents an interesting strategy and development pathway. However, it comes with a set of challenges. Here, we have attempted to address the first challenge that academic clinical researchers face when it comes to repurposing drugs in their disease of interest: navigating the scientific literature to filter putative drugs.27 The other main challenges are pharmacological, clinical, strategic, regulatory, and financial. From a clinical trial perspective an efficient way to test multiple candidates is by setting up efficient trials, such as multi-arm multi-stage (MAMS) trials.28 This would allow the pace of clinical research to be accelerated and expose as few patients as possible to ineffective or toxic regimens. Large platform or MAMS trials that address global clinical cancer research questions, such as treatment of cervical cancer, are yet to be developed. Collaboration between institutions in low- or middle-income countries and high-income countries and substantial funding will be essential for these efforts to deliver and ultimately succeed in improving cancer patient outcomes globally.

CONCLUSION

This study resulted in a list of potential candidates that are worth evaluating in cervical cancer. Although some of the drugs warrant additional preclinical and clinical investigation, repurposing of approved drugs may bring additional therapeutic options to patients. An efficient and coordinated manner to evaluate several of these drug candidates would be in platform trials, which are a type of randomized clinical trial that simultaneously compare multiple intervention groups against a single control group. This type of trial design can evaluate treatment options with fewer patients, less time, and with potentially higher success rates than traditionally designed trials.

Author affiliations

1Anticancer Fund, Meise, Belgium
2Department of Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
3Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
4The George Pantziarka TP53 Trust, London, UK
5Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India

Contributors RC and GB drafted the manuscript. SP, IB, PP, SC, RN reviewed the manuscript and provided input on the manuscript. PP ran the queries and prepared the databases for off-line processing. RC and GB screened the abstracts and trials for relevance. RC and GB are the guarantors of the manuscript. All authors contributed to the manuscript and approved the submitted version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests RN receives research grants from Dutch Research Council, Dutch Cancer Society, Varian, Elekta, Accuray and is an advisory board MSD: Global Gynecologic Cancer MDT Forum 2021.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

2. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144–53.

3. Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IIB, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 2018;36:1548–55.

4. Kenter G, Greggi S, Vergote I, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage IIB-IIIB cervical cancer. EORTC 55094. JCO 2019;37:5503.

5. Horeweg N, Mittal P, Gradovska PL, et al. Adjuvant systemic therapy after chemoradiation and brachytherapy for locally advanced cervical cancer: a systematic review and meta-analysis. Cancers 2021;13:13.

6. Mileshkin LR, Moore KN, Barnes E, et al. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK trial (ANZGOG 0902, RT0G 1174, NRG O274). JCO 2021;39:LB6A3.

7. Tewari KS, Skill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734–43.

8. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 2021;385:1856–67.

9. Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022;386:544–55.

10. Naumann RW, Oenin A, Meyer T, et al. Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (PTS) with recurrent/metastatic cervical cancer: results from CheckMate 358. Ann Oncol 2019;30:989–98.

11. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:609–19.

12. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019;18:41–58.

13. Bertolino F, Sukhatme VP, Bouche G. Drug repurposing in oncology -patient and health systems opportunities. Nat Rev Clin Oncol 2015;12:732–42.